Emerging biological roles for erythropoietin in the nervous system
The DOI matches its Crossref record; 107 of the 108 references it cites were found in a registry or an index.
Abstract
Erythropoietin mediates an evolutionarily conserved, ancient immune response that limits damage to the heart, the nervous system and other tissues following injury. New evidence indicates that erythropoietin specifically prevents the destruction of viable tissue surrounding the site of an injury by signalling through a non-haematopoietic receptor. Engineered derivatives of erythropoietin that have a high affinity for this receptor have been developed, and these show robust tissue-protective effects in diverse preclinical models without stimulating erythropoiesis. A recent successful proof-of-concept clinical trial that used erythropoietin to treat human patients who had suffered a stroke encourages the evaluation of both this cytokine and non-erythropoietic derivatives as therapeutic agents to limit tissue injury.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Erythropoietin was originally recognized via its role in erythropoiesis [2145-2147] (hence its name, of course), but it has become evident that it has many other roles, and in particular it is observed phenomenologically that erythropoietin (and non-erthyropoetic derivatives) is protective in a number of inflammatory conditions that accompany many diseases such as those listed above [940,942,2148-”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [2150]
Citations
Cites
Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
Brines, M. L., Ghezzi, P., Keenan, S., Agnello, D., de Lanerolle, N. C., Cerami, C., Itri, L. M., & Cerami, A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.19.10526 · Cited by 1,402 · cited 1×
“Follow-up studies confirmed erythropoietin to be a neuroprotective factor in hypoxic-ischaemic, traumatic, excitotoxic and inflammatory injurie”
BackgroundSelf-citationHIF-1 and mechanisms of hypoxia sensing
Semenza, G. L. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00194-0 · Cited by 1,268
Henke, M., Laszig, R., Rübe, C., Schäfer, U., Haase, K.-D., Schilcher, B., Mose, S., Beer, K. T., Burger, U., Dougherty, C., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14567-9 · Cited by 1,250 · cited 1×
“It is worrying that some cancer patients treated with rhEPO have also shown tumour expansio”
BackgroundErythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, H.-H., Breiter, N., Jacob, S., Knerlich, F., et al. (2002) · Molecular Medicine · doi:10.1007/bf03402029 · Cited by 1,028
Self-citationJuhaszova, M., Zorov, D. B., Kim, S.-H., Pepe, S., Fu, Q., Fishbein, K. W., Ziman, B. D., Wang, S., Ytrehus, K., Antos, C. L., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci19906 · Cited by 1,026
Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress
Sirén, A.-L., Fratelli, M., Brines, M., Goemans, C., Casagrande, S., Lewczuk, P., Keenan, S., Gleiter, C., Pasquali, C., Capobianco, A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051606598 · Cited by 1,019
Self-citationIn vivo evidence that erythropoietin protects neurons from ischemic damage
Sakanaka, M., Wen, T.-C., Matsuda, S., Masuda, S., Morishita, E., Nagao, M., & Sasaki, R. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.8.4635 · Cited by 949 · cited 1×
“Follow-up studies confirmed erythropoietin to be a neuroprotective factor in hypoxic-ischaemic, traumatic, excitotoxic and inflammatory injurie”
BackgroundDigicaylioglu, M., & Lipton, S. A. (2001) · Nature · doi:10.1038/35088074 · Cited by 923 · cited 1×
“Furthermore, although it has been reported that STAT is part of erythropoietin's neuroprotective signalling cascade in vitro , in vivo studies largely have not supported the involvement of STATs in erythropoietin cytoprotectio”
BackgroundPurification of human erythropoietin.
Miyake, T., Kung, C. K., & Goldwasser, E. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)63387-9 · Cited by 886
Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic
Leist, M., Ghezzi, P., Grasso, G., Bianchi, R., Villa, P., Fratelli, M., Savino, C., Bianchi, M., Nielsen, J., Gerwien, J., et al. (2004) · Science · doi:10.1126/science.1098313 · Cited by 803
Self-citation
Cited by
Items 301–400 of 527
Shchelochkov, O. A., Farmer, C., Chlebowski, C., Adedipe, D., Ferry, S., Manoli, I., Pass, A. R., McCoy, S., Ryzin, C. V., Sloan, J. L., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02385-5 · Cited by 17
Autocrine function of erythropoietin in IGF-1-induced erythropoietin biosynthesis
Kim, I., Kim, C. H., Yim, Y. S., & Ahn, Y. S. (2008) · Neuroreport · doi:10.1097/wnr.0b013e32831743fb · Cited by 17
“It also has nonhematopoietic roles such as neuroprotection and neurogenesis [6].”
BackgroundKim, M. S., Seo, Y. K., Park, H. J., Lee, K. H., Lee, K. H., Choi, E. J., Kim, J. K., Chung, H. L., & Kim, W. T. (2010) · Korean Journal of Pediatrics · doi:10.3345/kjp.2010.53.10.898 · Cited by 17
Sollinger, C. A., Lillis, J. A., Malik, J. T., Getman, M. R., Pröschel, C., & Steiner, L. A. (2017) · Scientific Reports · doi:10.1038/s41598-017-14366-0 · Cited by 19
Fisher, C., & Lilge, L. D. (2014) · Journal of Innovative Optical Health Sciences · doi:10.1142/s1793545815300050 · Cited by 17
Targeted delivery of growth factors in ischemic stroke animal models
Rhim, T., & Lee, M. (2016) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2016.1144588 · Cited by 18
Zhu, L., Huang, L., Wen, Q., Wang, T., Qiao, L., & Jiang, L. (2017) · Neuroscience Letters · doi:10.1016/j.neulet.2017.03.024 · Cited by 16
Liang, F., Guan, H., Li, W., Zhang, X., Liu, T., Liu, Y., Mei, J., Jiang, C., Zhang, F., Luo, B., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658715 · Cited by 17
Chiu, P.-C., Liou, H., Ling, T., & Shen, L. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00845-2 · Cited by 16
He, M., Kittur, F. S., Hung, C., Zhang, J., Jing, L., Sane, D. C., Li, P. A., & Xie, J. (2021) · Translational Stroke Research · doi:10.1007/s12975-021-00943-z · Cited by 16
Erythropoietin-responsive sites in normal and malignant human lung tissues
Yasuda, Y., Hara, S., Hirohata, T., Koike, E., Yamasaki, H., Okumoto, K., & Hoshiai, H. (2010) · Anatomical Science International · doi:10.1007/s12565-010-0081-7 · Cited by 16
Erythropoietin, progenitors, and repair
Aydin, Z., Duijs, J. M. G. J., Bajema, I. M., van Zonneveld, A. J., & Rabelink, T. J. (2007) · Kidney International · doi:10.1038/sj.ki.5002483 · Cited by 16
Gene therapy for the treatment of sensory neuropathy
Mata, M. M., Chattopadhyay, M., & Fink, D. J. (2006) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.6.5.499 · Cited by 19
Chattong, S., Tanamai, J., Kiatsomchai, P., Nakatsu, M., Sereemaspun, A., Pimpha, N., Praditpornsilpa, K., Rojanathanes, R., Sethpakadee, A., Tungsanga, K., et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.02123.x · Cited by 15
Khairallah, M. I., Kassem, L. A., Yassin, N. A. E., Din, M. A. G. E., Zekri, M., & Attia, M. (2013) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2014.9.21 · Cited by 15
Voituron, N., Jeton, F., Cholley, Y., Hasnaoui-Saadani, R. E., Marchant, D., Quidu, P., Favret, F., Richalet, J., & Pichon, A. (2014) · Physiological Reports · doi:10.1002/phy2.223 · Cited by 15
Hooshmandi, E., Moosavi, M., Katinger, H. W. D., Sardab, S., Ghasemi, R., & Maghsoudi, N. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05309-6 · Cited by 16
The Burden of Neurosarcoidosis: Essential Approaches to Early Diagnosis and Treatment
Voortman, M., Stern, B. J., Saketkoo, L. A., & Drent, M. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0040-1710576 · Cited by 15
Hong, J. M., Choi, M. H., Park, G. H., Shin, H. S., Lee, S., Lee, J. S., & Lim, Y. C. (2022) · Stroke · doi:10.1161/strokeaha.122.038650 · Cited by 15
Arik, E., Heinisch, O., Bienert, M., Gubeljak, L., Slowik, A., Reich, A., Schulz, J. B., Wilhelm, T., Huber, M., & Habib, P. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.915348 · Cited by 17
Non‐Clinical Safety Studies on Biosimilar Recombinant Human Erythropoietin
Parnham, M. J., Schindler‐Horvat, J., & Kozlović, M. (2007) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2007.00028.x · Cited by 15
Thrombopoietin inhibits nerve growth factor-induced neuronal differentiation and ERK signalling
Samoylenko, A., Byts, N., Rajalingam, K., von Ahsen, N., Rapp, U. R., Ehrenreich, H., & Sirén, A. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2007.10.006 · Cited by 15
Effects of Serotonin on Erythropoietin Expression in Mouse Hippocampus
Choi, M., & Son, H. (2013) · Experimental Neurobiology · doi:10.5607/en.2013.22.1.45 · Cited by 15
Arthur, E., Kittur, F. S., Lin, Y., Hung, C., Sane, D. C., & Xie, J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00208 · Cited by 15
Review of the Role of Erythropoietin in Critical Leg Ischemia
Joshi, D., Tsui, J. C. S., Ho, T. K., Selvakumar, S., Abraham, D., & Baker, D. (2010) · Angiology · doi:10.1177/0003319709358697 · Cited by 15
“Adapted from Brines et al.(28) 544 Angiology 61(6)”
MethodEnhanced brain release of erythropoietin, cytokines and NO during carotid clamping
Carelli, S., Ghilardi, G., Bianciardi, P., Latorre, E., Rubino, F. M., Bissi, M., Giulio, A. M. D., Samaja, M., & Gorio, A. (2015) · Neurological Sciences · doi:10.1007/s10072-015-2398-4 · Cited by 14
Effects of erythropoietin on bile duct ligation-induced neuro-inflammation in male rats
Golshani, M., Basiri, M., Shabani, M., Aghaei, I., & Asadi‐Shekaari, M. (2019) · AIMS neuroscience · doi:10.3934/neuroscience.2019.2.43 · Cited by 14
Sayed, R. H., Ghazy, A. H., & Yammany, M. F. E. (2022) · Inflammopharmacology · doi:10.1007/s10787-022-00935-x · Cited by 14
Celorrio, M., Rhodes, J., Shumilov, K., Moritz, J., Xiao, S., Anabayan, I., Sauerbeck, A. D., Kummer, T. T., & Friess, S. H. (2022) · Brain Research · doi:10.1016/j.brainres.2022.148074 · Cited by 14
Erythropoietin re-wires cognition-associated transcriptional networks
Singh, M., Zhao, Y., Gastaldi, V. D., Wojcik, S. M., Curto, Y., Kawaguchi, R., Merino, R. M., Garcia‐Agudo, L. F., Taschenberger, H., Brose, N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40332-8 · Cited by 16
Therapeutic strategies to target acute and long-term sequelae of pediatric traumatic brain injury
Huh, J. W., & Raghupathi, R. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.06.025 · Cited by 16
Neuroprotective effects of EpoL against oxidative stress induced by soluble oligomers of Aβ peptide
Castillo, C., Fernández‐Mendívil, C., Buendía, I., Saavedra, P., Meza, C., Parra, N. C., López, M. G., Toledo, J. R., & Fuentealba, J. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101187 · Cited by 15
Wang, S., Wu, Z., Chiang, P., Fink, D. J., & Mata, M. M. (2011) · Gene Therapy · doi:10.1038/gt.2011.166 · Cited by 16
Effects of erythropoietin on intracellular calcium concentration of rat primary cortical neurons
Andoh, T., Echigo, N., Kamiya, Y., Hayashi, M., Kudoh, I., & Goto, T. (2011) · Brain Research · doi:10.1016/j.brainres.2011.02.077 · Cited by 14
Kai, S., Tanaka, T., Matsuyama, T., Suzuki, K., & Hirota, K. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.03.020 · Cited by 13
Kittur, F. S., Lin, Y., Arthur, E., Hung, C., Li, P. A., Sane, D. C., & Xie, J. (2019) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2019.01.004 · Cited by 16
“Moreover, for cytoprotective function, EPO has been suggested to bind to a heterodimeric receptor consisting of EPOR and β-CR [25,74].”
BackgroundContaldo, C., Lindenblatt, N., Elsherbiny, A., Högger, D. C., Borozadi, M. K., Vetter, S., Lang, K. S., Handschin, A. E., & Giovanoli, P. (2010) · Shock · doi:10.1097/shk.0b013e3181fd0700 · Cited by 13
Park, G. H., Shin, H. S., Choi, E. S., Yoon, B. S., Choi, M. H., Lee, S., Lee, K.-E., Lee, J. S., & Hong, J. M. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104538 · Cited by 13
A Comparative Analysis of Erythropoietin and Carbamoylated Erythropoietin Proteome Profiles
Tiwari, N. K., Sathyanesan, M., Kumar, V., & Newton, S. S. (2021) · Life · doi:10.3390/life11040359 · Cited by 15
Erythropoietin Protects Against Acute Kidney Injury and Failure
Johnson, D. W., Vesey, D. A., & Gobe, G. C. (2010) · The Open Drug Discovery Journal · doi:10.2174/1877381801002020008 · Cited by 14
Erythropoietin Potentiates EDHF-Mediated Dilations in Rat Middle Cerebral Arteries
Shafi, N. I., Andresen, J. J., Marrelli, S. P., & Bryan, R. M. (2008) · Journal of Neurotrauma · doi:10.1089/neu.2007.0347 · Cited by 13
Simoni, J. M., Simoni, G., Moeller, J. F., Feola, M., Griswold, J., & Wesson, D. E. (2012) · Artificial Organs · doi:10.1111/j.1525-1594.2011.01431.x · Cited by 13
Cañadillas, S., Ortega, R., Estepa, J.-C., Egea, J., González‐Menchen, A., Pérez-Seoane, C., López-Andréu, M., Ramírez, R., Tetta, C., Rodríguez, M., et al. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00343.2009 · Cited by 12
“However, it has been reported that EPO receptors (EPORs) are also expressed in nonerythroid cells (neurons, endothelial cells, cardiomyocytes, renal tubular cells, podocytes, and mesangial cells) which can respond to EPO treatment (17, 18, 22, 24, 27).”
BackgroundInfluentialHeinrich, R., Günther, V., & Miljus, N. (2017) · Vitamins and hormones · doi:10.1016/bs.vh.2017.02.004 · Cited by 13
Yamashita, T., Nonoguchi, N., Ikemoto, T., Miyatake, S., & Kuroiwa, T. (2010) · Neurological Research · doi:10.1179/016164110x12700393823336 · Cited by 12
Approaches to neuroprotective strategies in multiple sclerosis
Tselis, A. C., Khan, O. A., & Lisak, R. P. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.508070 · Cited by 12
Kang, S., Kang, J., Choi, J. C., Lee, J. S., Lee, C. S., & Shin, T. (2009) · Journal of Clinical Neurology · doi:10.3988/jcn.2009.5.1.39 · Cited by 12
Neuroprotective Agents in the Intensive Care Unit
Panahi, Y., Mojtahedzadeh, M., Najafi, A., Rajaee, S. M., Torkaman, M., & Sahebkar, A. (2018) · Journal of pharmacopuncture · doi:10.3831/kpi.2018.21.026 · Cited by 14
Experimental studies of erythropoietin protection following traumatic brain injury in rats
Xu, F., Yu, Z., Ding, L., & Zheng, S. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.723 · Cited by 12
Erythropoietin and Friedreich Ataxia: Time for a Reappraisal?
Boesch, S., & Indelicato, E. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00386 · Cited by 12
Therapeutic potential of erythropoietin in cardiovascular disease: Erythropoiesis and beyond
Westenbrink, B. D., Voors, A. A., Ruifrok, W.-P. T., van Gilst, W. H., & van Veldhuisen, D. J. (2007) · Current Heart Failure Reports · doi:10.1007/s11897-007-0030-5 · Cited by 12
Pleiotropic effects of erythropoietin in neuronal and vascular systems
Boogaerts, M. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x159588 · Cited by 12
Erythropoietin and ischemic conditioning – why two good things may be bad
Bührer, C., Felderhoff‐Mueser, U., & Wellmann, S. M. (2007) · Acta Paediatrica · doi:10.1111/j.1651-2227.2007.00335.x · Cited by 12
Miscellanea on Encephalopathies
Legname, G., & Zanusso, G. (2012) · InTech eBooks · doi:10.5772/1191 · Cited by 11
Rey, F., Messa, L., Maghraby, E., Casili, G., Ottolenghi, S., Barzaghini, B., Raimondi, M. T., Cereda, C., Cuzzocrea, S., Zuccotti, G., et al. (2022) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0046 · Cited by 11
Miskowiak, K. W., Inkster, B., Selvaraj, S., Goodwin, G. M., & Harmer, C. J. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0907-8 · Cited by 11
“However, if, instead, the effects seen in our 1-week neuroimaging study were carry-over effects on oxygen availability or neurotransmitter release (for review, see Brines and Cerami 2005), greater effects would be predicted at earlier time points.”
BackgroundEmerging drugs for primary progressive multiple sclerosis
Narayan, R., Forsthuber, T. G., & Stüve, O. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1463370 · Cited by 11
Ma, J., Yang, X., Xu, F., & Li, H. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.898191 · Cited by 13
“Therefore, cART can delay the progression of HAD, but cannot completely prevent the occurrence of HAND, and some studies (8, 9) have shown that the severity of cognitive impairment is not related to the cerebrospinal fluid and peripheral viral load, but is related to the lowest value of CD4+T cells.”
BackgroundErythropoietin Induces Homeostatic Plasticity at Hippocampal Synapses
Dias, R. B., Rodrigues, T. M., Rombo, D. M., Ribeiro, F. F., Rodrigues, J. S., McGarvey, J., Orcinha, C. R., Henley, J. M., & Sebastião, A. M. (2017) · Cerebral Cortex · doi:10.1093/cercor/bhx159 · Cited by 12
Li, Q.-R., Han, Y., Du, J.-B., Jin, H.-F., Zhang, J., Niu, M.-M., & Qin, J. (2018) · Life Science · doi:10.1016/j.lfs.2017.12.014 · Cited by 12
de Barros, A. G. C., Cristante, A. F., dos Santos, G. B., Natalino, R. J. M., Ferreira, R. J. R., & Filho, T. E. P. D. B. (2019) · Clinics · doi:10.6061/clinics/2019/e674 · Cited by 11
“Erythropoietin hormone plays a role in red cell homeostasis and seems to improve metabolism in many tissues (9).”
BackgroundZhou, Y., Sun, B., Guo, J., & Zhou, G. (2020) · Biomedical Reports · doi:10.3892/br.2020.1347 · Cited by 11
Ruifrok, W.-P. T., Westenbrink, B. D., de Boer, R. A., Hamer, I. J. W., Erasmus, M. E., Mungroop, H. E., Epema, A. H., Voors, A. A., van Veldhuisen, D. J., & van Gilst, W. H. (2010) · Netherlands Heart Journal · doi:10.1007/bf03091769 · Cited by 11
Cerit, H., Veer, I. M., Dahan, A., Niesters, M., Harmer, C. J., Miskowiak, K. W., Rombouts, S. A. R. B., & van der Does, W. A. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.09.005 · Cited by 11
Hung, P., Yeh, C., Hsiao, C., Muo, C., Hung, K., & Tsai, K. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019529 · Cited by 10
Neurorestoration therapeutics for neurodegenerative and psychiatric disease
Bednar, M. M., & Perry, A. (2012) · Neurological Research · doi:10.1179/1743132811y.0000000069 · Cited by 11
Butt, U. J., Hassouna, I. A., Garcia‐Agudo, L. F., Steixner-Kumar, A. A., Depp, C., Barnkothe, N., Zillmann, M. R., Ronnenberg, A., Bonet, V., Goebbels, S., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063164 · Cited by 10
Knorr, D. Y., Hartung, D., Schneider, K., Hintz, L., Pies, H. S., & Heinrich, R. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.648245 · Cited by 10
EPO has multiple positive effects on astrocytes in an experimental model of ischemia
Blixt, J., Song, Y., Wanecek, M., & Gunnarson, E. (2022) · Brain Research · doi:10.1016/j.brainres.2022.148207 · Cited by 10
Memişoğlu, A., Kolgazi, M., Yaman, A., Bahadir, E., Şirvancı, S., Yeğen, B. Ç., & Özek, E. (2016) · Neurochemical Research · doi:10.1007/s11064-016-2135-2 · Cited by 10
Kang, H., & Kim, H.-S. (2008) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.6.5.703 · Cited by 10
Activities of erythropoietin on tumors: An immunological perspective
Ghezzi, P., & Mengozzi, M. (2007) · European Journal of Immunology · doi:10.1002/eji.200737401 · Cited by 9
Knorr, D. Y., Schneider, K., Büschgens, L., Förster, J., Georges, N. S., Geurten, B. R. H., & Heinrich, R. (2022) · Scientific Reports · doi:10.1038/s41598-022-22035-0 · Cited by 9
Asialo-rhuEPO as a Potential Neuroprotectant for Ischemic Stroke Treatment
Kittur, F. S., Hung, C., Li, P. A., Sane, D. C., & Xie, J. (2023) · Pharmaceuticals · doi:10.3390/ph16040610 · Cited by 10
Ortiz, J. S. (2008) · Clinical & Translational Oncology · doi:10.1007/s12094-008-0237-2 · Cited by 9
“Interaction of high local concentrations of EPO with the EPOR and bCR complex receptors leads to activation of numerous genes associated with antiapoptosis, reduction of inflammatory cytokines, and maintenance of vascular flow, including also the same JAK-STAT and PI-3-K pathways involved in erythropoiesis activation…”
BackgroundYang, X., He, Y., LI, H.-Y., Liu, X., Chen, H., LIU, J.-B., Ji, W., WANG, B., & Chen, L. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2164 · Cited by 9
“EPO exerts protective effects against tissue destruction surrounding sites of injury by signaling through a nonhemopoietic receptor (31).”
BackgroundSafety of intravitreally administered recombinant erythropoietin (an AOS thesis).
Tsai, J. C. (2008) · PubMed · Cited by 9
Erythropoietin Increases GABAA Currents in Human Cortex from TLE Patients
Roseti, C., Cifelli, P., Ruffolo, G., Barbieri, E., Guescini, M., Esposito, V., Gennaro, G. D., Limatola, C., Giovannelli, A., Aronica, E., et al. (2019) · Neuroscience · doi:10.1016/j.neuroscience.2019.04.013 · Cited by 9
“Different studies have shown that EPO exerts potent neuroprotective effects in animal models of CNS disorders both in vitro (Bartesaghi et al., 2005; Brines et al., 2000; Dame et al., 2001; Genc et al., 2004) and in vivo, especially by enhancing neurogenesis (Shingo et al., 2001; Xiong et al., 2008; Kadota et al., 200…”
BackgroundInfluentialErythropoietin restrains the inhibitory potential of interneurons in the mouse hippocampus
Curto, Y., Carceller, H., Klimczak, P., Pérez-Rando, M., Wang, Q., Grewe, K., Kawaguchi, R., Rizzoli, S. O., Geschwind, D. H., Nave, K., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02528-2 · Cited by 10
Carbonell, T., & Rama, R. (2009) · Current Chemical Biology · doi:10.2174/2212796810903030238 · Cited by 10
Shi, Y., & Ma, X. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210524154519 · Cited by 9
An update on combination therapies for multiple sclerosis: where are we now?
Sørensen, P. S., Magyari, M., & Sellebjerg, F. T. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2289572 · Cited by 8
“Erythropoietin (EPO), a hematopoietic growth factor, has in experimental studies been found to be part of an endogenous neuroprotective system in the brain [107], and has been shown to promote axonal repair, neurogenesis, and angiogenesis [108].”
BackgroundNew Biomarkers in the Retina and RPE Under Oxidative Stress
Jin, W. (2012) · InTech eBooks · doi:10.5772/48785 · Cited by 8
Erythropoietin and amyotrophic lateral sclerosis: Plasma level determination
Carilho, R., de Carvalho, M. A., Kuehl, U., Pinto, S., Pinto, A. C., Kromminga, A., & Costa, J. (2011) · Amyotrophic Lateral Sclerosis · doi:10.3109/17482968.2011.584881 · Cited by 8
Constanthin, P. E., Contestabile, A., Petrenko, V., Quairiaux, C., Salmon, P., Hüppi, P. S., & Kiss, J. Z. (2020) · Development · doi:10.1242/dev.190249 · Cited by 8
“Given its neuroprotective effects (Brines and Cerami, 2005; Sirén and Ehrenreich, 2001), the therapeutic potential of EPO has been widely explored in recent years for treatment of hypoxic brain lesion (Byts and Sirén, 2009; Gonzalez and Ferriero, 2009; Juul, 2000; Wu et al.”
BackgroundDanigo, A., Magy, L., Richard, L., Desmoulière, A., Bourthoumieu, S., Funalot, B., & Demiot, C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113454 · Cited by 8
Doğu, B., Yüksel, N., Cekmen, M. B., & Çağlar, Y. (2010) · International Ophthalmology · doi:10.1007/s10792-010-9391-y · Cited by 8
“It is recognized that EPO also has a neuroprotective effect through a variety of mechanisms including the inhibition of apoptosis and the maintenance of vascular autoregulation [12, 15], and it is believed that EPO regulates the antiapoptotic, antioxidative, and antiinflammatory response to hypoxia/anoxia.”
BackgroundHematopoiesis and bone remodeling
Suda, T. (2011) · Blood · doi:10.1182/blood-2011-03-344127 · Cited by 8
Repurposed Drugs for the Treatment of Schizophrenia and Bipolar Disorders
Bumb, J. M., Enning, F., & Leweke, F. M. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113136660165 · Cited by 8
Çalışkan, M., Simsek, S., Vural, S., & Beşaltı, Ö. (2015) · Turkish Neurosurgery · doi:10.5137/1019-5149.jtn.14036-15.1 · Cited by 7
Nonhematopoietic effects of erythropoiesis-stimulating agents
JELKMANN, W. E. B., Depping, R., & Metzen, E. (2009) · Birkhäuser Basel eBooks · doi:10.1007/978-3-7643-8698-6_16 · Cited by 7
“Less conclusive evidence is available in proof of the idea that these effects are mediated by a putative heteroreceptor consisting of EPOR and the common cytokine beta receptor (βcR) [ 33 ] (Fig. 2). EPOR/βcR hypothesis is mainly based on the observation that erythropoietically inactive carbamoylated EPO (CEPO) provid…”
BackgroundZhang, W., Sun, B., Wang, X., Liu, J., Zhang, Z., & Geng, S. (2010) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2009.08.014 · Cited by 7
Neurodegeneration and Remyelination in Multiple Sclerosis
Nourbakhsh, B., & Waubant, E. L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800763-1.00013-0 · Cited by 8
Cha, J.-R., Kim, S., & Heo, T. (2011) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2011.04.019 · Cited by 7
Elliot‐Portal, E., Arias‐Reyes, C., Laouafa, S., Tam, R., Kinkead, R., & Soliz, J. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.701344 · Cited by 6
Guo, C., Li, W., Liu, Y., Tao, X., Mahaman, Y. A. R., Wang, J., Liu, R., Li, S., & Wang, X. (2024) · Advanced Science · doi:10.1002/advs.202406979 · Cited by 7
Liongue, C., & Ward, A. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26083498 · Cited by 6
“Moreover, another SPRY-domain containing protein, SPRY and SOCS box 2 (SPSB2), has been separately implicated in platelet production [53].”
Spaan, M., Groothuismink, Z. M. A., Koning, L., Roomer, R., Janssen, H. L. A., de Knegt, R. J., & Boonstra, A. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.04.003 · Cited by 6
Heikal, L., Ghezzi, P., Mengozzi, M., & Ferns, G. A. (2015) · Molecular Medicine · doi:10.2119/molmed.2015.00162 · Cited by 6
Midazolam inhibits the hypoxia-induced up-regulation of erythropoietin in the central nervous system
Matsuyama, T., Tanaka, T., Tatsumi, K., Daijo, H., Kai, S., Harada, H., & Fukuda, K. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.05.024 · Cited by 8
“The endogenous secretion of EPO in CNS is oxygen dependent (Noguchi et al., 2007) and has protective effects against hypoxic neuronal damages (Brines and Cerami, 2005).”
Background
Metadata
- Authors
- Brines, M., & Cerami, A.
- Corresponding author
- Brines, Michael
- Venue
- Nature Reviews Neuroscience
- Published
- 2005-06-01
- Volume
- 6
- Issue
- 6
- Pages
- 484-494
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2168867226
- Cited by
- 523
- References
- 108
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 6 · 2023: 8 · 2022: 18 · 2021: 21 · 2020: 13 · 2019: 25 · 2018: 17 · 2017: 16 · 2016: 21 · 2015: 19 · 2014: 22 · 2013: 30 · 2012: 38
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Update notices
- correction (2005-08-01)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- www.springer.com/tdm (unspecified)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heme Oxygenase-1 and Carbon Monoxide
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Keywords
- erythropoietin, nervous system, neuroprotection, tissue damage, stroke, neuroinflammation
- MeSH terms
- Animals, Central Nervous System, Erythropoietin, Humans, Signal Transduction, Receptors, Cytokine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.